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Background: During the last decade nanoparticles have gained attention as promising drug delivery agents that
can transport through the blood brain barrier. Recently, several studies have demonstrated that specifically targeted
nanoparticles which carry a large payload of therapeutic agents can effectively enhance therapeutic agent delivery
to the brain. However, it is difficult to draw definite design principles across these studies, owing to the differences
in material, size, shape and targeting agents of the nanoparticles. Therefore, the main objective of this study is to
develop general design principles that link the size of the nanoparticle with the probability to cross the blood brain
barrier. Specifically, we investigate the effect of the nanoparticle size on the probability of barbiturate coated GNPs
to cross the blood brain barrier by using bEnd.3 brain endothelial cells as an in vitro blood brain barrier model.
Results: The results show that GNPs of size 70 nm are optimal for the maximum amount of gold within the brain
cells, and that 20 nm GNPs are the optimal size for maximum free surface area.
Conclusions: These findings can help understand the effect of particle size on the ability to cross the blood brain
barrier through the endothelial cell model, and design nanoparticles for brain imaging/therapy contrast agents.
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The diagnosis and therapy of central nervous system
(CNS) and brain pathologies, including Parkinson’s dis-
ease, Alzheimer’s disease, epilepsy and glaucoma, are in-
adequate because of the limited ability to deliver drugs
and imaging contrast agents across the blood brain barrier
(BBB) [1]. The BBB separates circulating blood from the
brain extracellular fluid (BECF) in the CNS and protects
the brain from various circulating toxins and infected cells
[2]. It is estimated that more than 98% of small molecular
weight drugs and practically 100% of large molecular
weight drugs developed for CNS pathologies do not read-
ily cross the BBB [3]. Therefore, it is extremely important
to investigate the BBB penetration mechanism in order to
treat and prevent brain disorders. To improve brain pene-
tration for therapeutic agents, medicinal chemistry and* Correspondence: rachela.popovtzer@biu.ac.il
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plored and developed widely [4].
During the last decade, nanoparticles have gained atten-
tion as promising drug delivery agents that can transport
across the BBB and increase the uptake of appropriate
drugs in the brain [1,4-6]. Nanoparticles increase the dur-
ation of drug circulation in the blood, which facilitates drug
ability to interact with specific molecules expressed on the
luminal side of BBB endothelial cells, and consequently to
cross the BBB. In addition, nanoparticles can be engineered
to provide designed functionalities using standard proce-
dures in nanotechnology [7-10]. The type and number of
linkers on the surface of the nanoparticles, as well as the
size of the nanoparticles themselves, can be modulated to
increase their ability to cross the BBB. Gold nanoparticles
(GNPs) have attracted enormous scientific interest due to
properties that make them useful for a large variety of
biological and chemical applications [11-14]. Their major
advantages are the ability to be synthesized at diverse
sizes, their chemical stability and their unique optical
properties [7,15,16]. Their surface has a strong bindinghis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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allows by simple chemistry, surface conjugation with
various peptides, proteins, antibodies and other biomol-
ecules [17-19]. Most importantly, GNPs can be traced
noninvasively in vivo by CT imaging, due to their high
atomic number [20-24], and can be quantitatively de-
tected ex vivo by atomic absorption methods.
It has been well demonstrated that the size, coating
and surface charge of nanoparticles have a crucial im-
pact on the intracellular uptake process [25]. Several
studies, which investigated the effect of the size of nano-
particles on cellular uptake, revealed different conclu-
sions; One study [25] compared between 14, 30, 50, 74
and 100 nm GNPs and reported that the highest uptake
was detected for 50 nm GNPs, as reported in other stud-
ies [26,27], while another group showed that 20 nm
GNP gave the best results [28]. However, differences in
material, size and shape of the nanoparticles, variability
between receptors (e.g., degree of receptor overexpres-
sion) and divergent cell types, make it difficult to draw
definite design principles across these studies [25,29].
In the present study, the effect of nanoparticle size on
the probability to cross the BBB was investigated using
the bEnd.3 brain endothelial cell model. The BBB is
formed from a single layer of endothelial cells, which are
joined by tight junctions, in the cerebrovascular capillar-
ies and end-feet astrocytes that cover the surface area of
the capillary. Therefore, the bEnd.3 model is the first
barrier between the blood and the brain and has a crit-
ical influence on the probability to cross the BBB. This
BBB cellular model has been widely used in the last few
years, and is considered an attractive candidate for an
in vitro model of the BBB [30-32].
Normal transition through the BBB can be performed
by diffusion transport, carrier systems and receptor-
mediated endocytosis [1]. Entrance of GNPs to these
cells can indicate penetration through the BBB. This
in vitro model does not represent abnormal BBB such as
in brain tumors [33].
GNPs of various sizes (20, 50, 70 and 110 nm) were
synthesized and coated with barbiturate, which is a mol-
ecule that can easily penetrate the BBB [34]. Therefore,
coating GNPs with barbiturate molecules will facilitate
their penetration through the BBB, both for therapy and
imaging applications. While several studies reported thatFigure 1 TEM images of (A) 20, (B) 50, (C) 70 and (D) 110 nm GNPs (sreceptor-mediated endocytosis has been shown to be the
most efficient transport mechanism through the BBB,
especially for large molecules, proteins and nanoparticles
[18,25], we hypothesize that there is an interaction
between the barbiturate molecule and the brain endo-
thelium that triggers particle uptake (probably through
pinocytosis [35]).
Results and discussion
GNP synthesis, conjugation and characterization
We have successfully synthesized GNPs in various sizes,
ranging from 20 nm up to 110 nm. Particles size, shape
and uniformity were measured using transmission
electron microscopy (TEM) and proven to be 20, 50, 70
and 110 nm diameter spheres (Figure 1). It is demon-
strated that the smallest GNPs (20 nm) have a relatively
large size distribution (20%), while larger GNPs are
more homogeneous, with have a very narrow size distri-
bution (~2%). The average sizes that were obtained
from the TEM were 18 ± 4 nm, 51 ± 1 nm, 67 ± 1 nm
and 108 ± 1 nm.
The difference in GNP size was also obtained using
UV–vis spectroscopy. Figure 2 shows a correlation be-
tween the size of the GNP and its spectrum. It can be seen
that when the GNPs are enlarged, there is a red shift in
the surface plasmon resonance (SPR) peak of the particles,
from ~525 nm to ~580 nm [36].
The size difference and efficiency of the GNP coating
(both MDDA and barbiturate) were confirmed by the de-
crease (absolute value) of the zeta-potential and by the
UV–vis Plasmon resonance shift and broadening (Figure 3).
An expanded signal was observed following each layer-
coating because the organic substance absorbs more en-
ergy from the irradiated light. The GF-GNPs were stable
for up to three months, confirmed by retention of their
plasmon resonance.
Size distribution of the barbiturate coated GNPs was
also determined using DLS (Figure 4). The average sizes
obtained from the DLS were 23 ± 13, 65 ± 22, 84 ± 26 and
120 ± 30 nm for the 20, 50, 70 and 110 nm GNPs, respect-
ively. The larger size of the particles obtained by the DLS
is due to the hydrodynamic diameter of particles. Similar
to the TEM results, the 20 nm GNPs have a relatively
large size distribution, while the larger GNPs are found to
be more homogeneous.cale bar 100 nm).
Figure 2 UV–vis spectroscopy of 20, 50, 70 and 110 nm GNP.
Each size exhibits a peak at a different wavelength: 525, 530, 540
and 570, respectively. When the GNPs are enlarged, there is a red
shift in the surface plasmon resonance (SPR) peak of the particles,
from 525 nm to 570 nm.
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In a control experiment, we compared between the intra-
cellular uptake of barbiturate coated GNPs and mPEG
coated nanoparticles, both of size 20 nm. Results showed
that barbiturate coated GNPs had high uptake in the
bEnd.3 model, while the control GNPs showed a negli-
gible amount of uptake by the cells, which could not be
detected by FAAS (Data not shown).
The results showed that intracellular uptake of GNPs
is clearly dependent on GNP size. Figure 5 shows the totalFigure 3 Characterization of the GNPs. Top: UV–vis Spectroscopy
of bare GNPs, MDDA coated GNPs and MDDA + Barbiturate coated
GNPs, for 20 nm GNPs. An expanded signal was observed following
each layer of coating, confirming the chemical coating. Bottom:
zeta-potential measurements at the various stages of GNP coatings
for each GNP size. The significant difference obtained (both by
zeta-potential and UV–vis Spectroscopy) following each chemical
step demonstrates the efficiency of the chemical coating.amount of gold per cell for the various sizes of GNPs (20,
50, 70 and 110 nm). Results clearly demonstrate that
70 nm GNPs produce the largest amounts of gold uptake
per cell (0.21 ± 0.03 ng, about 90% the GNPs), while for
the 20 nm GNPs the uptake was only 0.12 ± 0.03 ng
(about 50% of the GNPs) per brain endothelial cell. A
T-test performed on these results showed a significant
difference (P value <0.05) between the different sizes
(Figure 5). Once we had quantitatively measured (using
FAAS) the total amount of gold bound to a single can-
cer cell, the exact number of nanoparticles and the GNP
surface area per cell could be calculated. When the total
free surface area was examined, 20 nm GNPs had the
maximum free surface area per cell. The free surface
area decreased with the increase in GNP size (Figure 6).
A T-test was performed on these results and showed a
significant difference (P value <0.05) between the differ-
ent sizes. Table 1 shows the total Au mass, the number
of GNPs of different sizes and the surface area of the
GNPs bound to a single brain endothelial cell.
We have further investigated, using confocal micros-
copy and fluorescent coated barbiturate-GNPs, the inter-
action between the nanoparticles and the bEnd.3 cells.
Serial z-sections of the cells, each 0.5 μm in thickness,
demonstrated fluorescence activity in all the sections
between 2 and 7 μm from the surface of the cells indi-
cating that large part of the nanoparticles were internal-
ized by the cells, while some nanoparticles also bound to
the cell surface. Figure 7 shows confocal microscopy of
midsection of bEnd.3 cell after incubation of 30 min
with barbiturate coated GNPs.
Results demonstrated that intracellular uptake of GNPs
is strongly dependent on GNP size. Different biomedical
applications require different considerations: for example,
when GNPs serve as CT contrast agents or as drug deliv-
ery carriers (by drug encapsulation into the GNPs), the
highest amount of gold is required (70 nm). However,
when GNPs serve as drug delivery carriers by binding the
drug molecules to the surface of the GNPs, the highest
free surface area is needed, and thus the appropriate size
would be 20 nm.Conclusions
In order to develop general design principles for nano-
particles to be used as in vivo imaging contrast agents or
drug delivery agents, this study investigated the effect of
nanoparticle size on the probability to cross the BBB,
using the endothelial brain cell model. Results showed
that the intracellular uptake of GNPs is dependent on
GNP size, and the appropriate size should be determined
according to the desired application. These results may
accelerate the development of general design principles
for GNPs to cross the BBB, and help to meet the great
Figure 4 DLS size distribution analysis for (A) 20, (B) 50, (C) 70 and (D) 110 nm GNPs. The average sizes obtained from the DLS were 23 ± 13,
65 ± 22, 84 ± 26 and 120 ± 30 nm for the 20, 50, 70 and 110 nm GNPs, respectively.
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ities for brain diseases and disorders.
Methods
GNP-synthesis and conjugation
Synthesis of 20 nm GNPs
GNPs were synthesized by citrate reduction of Hydrogen
tetrachloroaurate(III) trihydrate (HAuCl4, Strem) [37].
414 μL of 50% w/V of HAuCl4 solution in 200 mLFigure 5 Quantitative measurements using FAAS of Au per cell,
for different sizes of GNPs. Each cell sample contained 1.3×106
cells. Results clearly demonstrate that 70 nm GNPs produce the
largest amounts of gold uptake per cell. Results are presented as the
total amount of gold (ng) per cell, mean ± S.D of three samples.
*P < 0.05, Student’s t-test.purified water was boiled in an oil bath on a heating
plate while being stirred. After boiling, 4 mL of a 10%
trisodium citrate solution was added and the mixture
was stirred while boiling for another 5 minutes. The re-
ducing agent, citrate, has a limited ability to synthesize
GNPs that are larger than 30 nm, and therefore, the re-
ducing agent MSA (2-mercaptosuccinic acid, Molekula),
which enables synthesis of larger GNPs, was used. For
GNP synthesis, 15 ± 1.5 nm gold seeds were first pre-
pared. A mixture of MSA and HAuCl4 solutions leads
to the growth of the gold seeds. Various amounts of
MSA and gold solution were added for each GNP size,
as detailed below.Figure 6 Calculated total free surface area per cell, for different
sizes of GNPs. The free surface area decreased with the increase in
GNP size. Results are presented as GNP surface area per cell, mean ± S.
D of three samples. *P < 0.05, Student’s t-test.
Table 1 Quantitative flame atomic absorption
measurements of GNP total Au mass (ng), total GNP
volume (nL) and total free surface area (μm2) per
single cell
GNP size (nm) Au/cell (ng) Total volume (nl) Total surface (μm2)
20 0.12 ± 0.03 6E−6 ± 1.05−6 1800 ± 545
50 0.17 ± 0.02 8.7−6 ± 7.6−7 1040 ± 158
70 0.21 ± 0.03 1.08−5 ± 8.6−7 926 ± 126
110 0.16 ± 0.004 8.4−6 ± 1.04−7 379 ± 8
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were synthesized and coated with a layer of Methoxy-
PEG-SH (mPEG-SH). This layer reduces nonspecific in-
teractions and increases blood circulation time of the
nanoparticles [38,39].Synthesis of seed solution for GNPs at 50, 70, and 110 nm
10 mL of purified water was mixed with 10.4 μL of 50%
w/V of HAuCl4 solution. The solution was stirred and
boiled on a heating plate. To the stirred solution, 100 μL
of Na3 citrate (8.8% weight percentage) was added and the
mixture was stirred and boiled for another 5 minutes (the
solution was diluted with water to a volume of 50 mL).Synthesis of 50, 70 and 110 nm GNPs in Growth solution
For synthesis of 50 nm GNPs, 200 mL of purified water
was mixed with 6.5 mL seed solution. 88 μL of 50% w/V
of HAuCl4 and 7.5 mL 0.04 M MSA solution was added
while stirring, and the mixture was stirred for another
half hour. For synthesis of 70 nm GNPs, 176.8 μL of 50%
w/V of HAuCl4 solution and 15 mL 0.04 M MSA solution
was added while stirring. The mixture was stirred for an-
other half hour. For synthesis of 110 nm GNPs, another 3
portions of 176.8 μL of 50% w/V of HAuCl4 solution and
15 mL 0.04 M MSA solution was added after the half hour
of stirring.Figure 7 Confocal images of bEnd.3 cells after 30 min of incubation w
bright field, B: Cell membrane staining and C: fluorescent coated barbitura
were imaged using Leica TCS SP5 with Acousto-Optical Beam Splitter micrConjugation of MDDA and Barbiturate to the GNPs
The linker MDDA (12-Mercaptododecanoic acid, Sigma-
Aldrich) conjugates between the GNP and the barbiturate.
One side of the MDDA chain (thiol) connects to the gold
via semi-covalent bonding, while the other side of the
MDDA chain, carboxylic acid, binds to the negatively
charged oxygen of the barbiturate. To each solution of
the various GNP sizes, MDDA was added in excessive
amounts, and the mixture was stirred for another four
hours. Following this step, the solutions were centrifuged in
order to reach higher concentrations. Next, the activating
agents EDC (1-Ethyl-3-(3-dimethylaminopropyl) carbodii-
mide HCl, Thermo Scientific) and NHS (N-Hydroxysulfo-
succinimide sodium salt, Chem-Impex International) were
added to the mixture together with the barbiturate, and
stirred overnight (Figure 8). The solutions were centri-
fuged again in order to increase concentration.
GNP characterization
The size, shape and uniformity of the GNPs were mea-
sured using transmission electron microscopy (TEM, JEM-
1400, JEOL). In addition, GNP size was measured using
ultraviolet–visible spectroscopy (UV-1650 PC; Shimadzu
Corporation, Kyoto Japan) and Dynamic Light Scattering
(DLS). Conjugation of the barbiturate to the linkers was
verified using Zeta potential and Fourier Transform Infra-
red (FTIR).
Brain endothelial cell model
As an in vitro model of the BBB, the mouse brain endo-
thelial cell line (bEnd.3, American Type Culture Collection
Manassas, VA) was used [30,31,40]. Cells were grown in
DMEM with 4.5 g/L glucose, 10% FBS, 3.7 g/L sodium bi-
carbonate, and 4 mM glutamine, and maintained in a hu-
midified cell culture incubator at 37°C.
In vitro experiments
Each different sized group of GNPs was incubated with
the brain endothelial cells (1.3 × 106) for a quantitative
cell uptake study (each experimental group was run inith 70 nm fluorescent coated barbiturate-GNPs complex. A: A
te-GNPs. The pictures were taken at the midsection of the cell. Sections
oscope.
Figure 8 Synthesis of GNPs. Schematic diagram of the synthesis
of GNPs and functionalization with barbiturate. In order to conjugate
the glucosamine to the GNP, the linker 12-Mercaptododecanoic acid
(MDDA) was utilized. EDC and NHS were added in order to activate
the carboxylic acids of the linker. One side of the MDDA chain (thiol)
connects to the gold via semi-covalent bonding, while the other
side, carboxylic acid, binds to the negatively charged oxygen of
the barbiturate.
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excessive amounts of GNPs were added to total medium
volume of 5 ml (identical amounts of gold per cell) and
the incubation time was 30 minutes at 37°C. The four
cell groups were incubated with 10 μL of either 20, 50,
70 or 110 nm GNPs (30 mg/mL). After incubation, the
medium was washed twice with PBS, followed by trypsin
treatment. The cells were centrifuged twice (7 minutes at
1000 rpm) in order to get rid of the unbound nanoparti-
cles. Finally, aqua-regia was added to the cells for ICP-MS
gold detection. The total amount of gold was compared
between the various GNP sizes.
Quantitative measurements of GNP uptake by brain
endothelial cells
Flame Atomic Absorption Spectroscopy (FAAS, SpectrAA
140, Agilent Technologies) was used in order to determine
the amount of the different sized GNPs within the cells.
Samples were melted with aqua regia acid (a mixture of
nitric acid and hydrochloric acid in a volume ratio of
(1:3)), filtered and diluted to a final volume of 5 mL. Gold
concentration was determined according to absorbance
values, compared to a calibration curve that was prepared
with known gold concentrations. All samples were ana-
lyzed by FAAS under the same experimental conditions.
Synthesis of fluorescent coated barbiturate-GNPs
Rodamine B and PEG-amine were attached to the
barbiturate-GNPs by stirring with EDC and NHS for
one hour. The mixture was stirred for 3 hours and then
centrifuged in order to remove excess rodamone B.Confocal microscopy experiment
Fluorescent coated barbiturate-GNPs were incubated
with the brain endothelial cells for 30 min at 37°C. Then,
cells were incubated with the fluorescent lipophilic dye,
DiO (Biotium, Inc., Hayward, CA) diluted in DMSO in a
final concentration of 10uM in the culture medium for
15 min at 37°C. The cells were subsequently washed
three times in PBS prior to confocal imaging using Leica
TCS SP5 with Acousto-Optical Beam Splitter micro-
scope to acquire fluorescent and bright field images.
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